AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Selective HDAC6 Inhibitor for the treatment of Alzheimer's and related diseases

Summary
Ronald Breslow, Ph.D.
Technology Benefits
Compounds target HDAC6 with 100-fold selectivity over HDAC1.Specific and selective inhibition of HDAC6 offers a therapy for the treatment of Alzheimer's and other neurological diseases while potentially minimizing off-target toxicities caused by pan-HDAC inhibitors. Patent information:Patent Pending (WO/2011/46855)Tech Ventures Reference: IR M10-078
Technology Application
Treatment of Alzheimer's disease through specific HDAC6 inhibition.Potentially useful for other central nervous system diseases such as Parkinson's and Huntington's.
Detailed Technology Description
Ronald Breslow, Ph.D.
*Abstract
None
*Inquiry
Beth KaudererColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
*IR
M10-078
*Principal Investigator
*Publications
P.A. Marks, R. Breslow. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, Vol. 25, Jan. 2007, pp. 84-90.
Country/Region
USA

For more information, please click Here
Mobile Device